Individualized Investigational Treatments for Life-threatening or Severely Debilitating Illnesses
This bill creates a new section of Florida law establishing a “patient right to try” for individualized investigational treatments for people with life-threatening or severely debilitating illnesses. It defines these treatments as drugs, biologics, or devices made uniquely for a single patient based on that patient’s genetic profile, including examples such as individualized gene therapies, antisense oligonucleotides, and neoantigen vaccines. To qualify, a patient must have a qualifying illness, consider FDA-approved options, receive a physician recommendation based on genomic or related analysis, and provide detailed written informed consent.
The bill allows eligible facilities and manufacturers operating within those facilities to provide such treatments, but it does not require them to do so. It also permits, but does not require, health plans, third-party administrators, and governmental agencies to cover related costs. The bill includes liability and consent protections, including a statement that heirs are not responsible for outstanding debt related to the treatment, and it limits potential legal claims against manufacturers and others involved if they acted in good faith and with reasonable care. It also bars state licensing boards and certain state entities from disciplining physicians solely for recommending these treatments, and prohibits state officials from blocking access to them.
The bill would add s. 499.0296 to the Florida Statutes and create a new legal framework for access to highly individualized investigational medical products. It would affect physicians, hospitals, eligible research facilities, manufacturers, insurers, third-party administrators, state agencies, and patients with severe or terminal conditions by setting conditions for access, informed consent, and limited liability. The measure also clarifies that it does not require hospitals to add new services, does not expand insurance coverage obligations under the Florida Insurance Code, and does not create a private cause of action against compliant manufacturers or care providers.
No committee transcripts or votes were provided, so there is no recorded debate or voting history to indicate support or opposition. Based on the bill text alone, the measure appears designed to expand patient access and physician discretion for experimental, personalized treatments while also limiting regulatory and legal barriers. The overall tone of the legislation is permissive and protective of patient choice and provider participation.
The main points of potential contention are the balance between patient access and medical/regulatory oversight, and the extent of liability protection for manufacturers and providers. Supporters would likely emphasize hope for patients with no effective approved options, physician autonomy, and the ability to pursue personalized therapies. Critics may focus on the experimental nature of the treatments, the possibility of unproven or harmful outcomes, the lack of required insurance coverage, and the bill’s restrictions on disciplinary action and legal claims. The requirement for detailed informed consent suggests the bill anticipates significant risk and controversy around safety and expectations.